MedTrace Logo

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

NCT02228525 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.

Conditions

Interventions

DRUG

selinexor (KPT-330)

Sponsors & Collaborators

Principal Investigators

  • Virginia Klimek, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-27
Primary Completion
2021-04-06
Completion
2021-04-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228525 on ClinicalTrials.gov